Abstract
Although pharmacogenomics has the potential to personalize drug therapy, economic evaluations showing clinical benefits and cost-effectiveness would go a long way to facilitate implementation. Testing of single genes has shown some benefits as well as limitations, and some investigators advocated the use of combinatorial pharmacogenomics approach. In addition, debates continue regarding the most appropriate way of evaluating cost-benefits. Review of alternative approaches to assessing clinical validity and utility, as well as cost-effectiveness of pharmacogenomics testing within the psychiatric discipline, show some promises and progress, as well as questions to be addressed, for these two important aspects of pharmacogenomics testing.
Original language | English (US) |
---|---|
Title of host publication | Pharmacogenomics |
Subtitle of host publication | Challenges and Opportunities in Therapeutic Implementation |
Publisher | Elsevier |
Pages | 385-394 |
Number of pages | 10 |
ISBN (Electronic) | 9780128126264 |
DOIs | |
State | Published - Jan 1 2018 |
Keywords
- Clinical utility
- Clinical validity
- Combinatorial
- Cost-benefit analysis
- Economic outcomes
- Personalized medicine
- Pharmacogenomics
- Psychiatry
ASJC Scopus subject areas
- Medicine(all)
- Pharmacology, Toxicology and Pharmaceutics(all)